Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 11/20 | 0.58 |
| ▸ | CASP6 | P55212 | 10/20 | 0.58 |
| ▸ | CASP8 | Q14790 | 10/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24939059 | 1.00 | CASP3 (0.58) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL25855233 | 0.92 | CASP3 (0.57) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL30276941 | 0.92 | CASP3 (0.51) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL24939471 | 0.92 | CASP3 (0.51) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL25307799 | 0.91 | CASP3 (0.50) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL24939265 | 0.91 | CASP3 (0.50) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL25307796 | 0.91 | CASP3 (0.50) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL30277009 | 0.91 | CASP3 (0.50) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL24939451 | 0.90 | CASP3 (0.57) | CASP3CASP6CASP8CTSLCTSB | |
| SCHEMBL24939425 | 0.90 | CASP3 (0.51) | CASP3CASP6CASP8CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | claimed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | CASP3 239/4885CASP6 378/4885CASP8 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.